This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Top Stock Reports for Micron Technology, Roche & UnitedHealth
by Mark Vickery
MU leads today's Zacks Research Daily, with AI-driven memory demand, strong DRAM pricing recovery and solid cash flow powering recent outperformance.
computers medical pharmaceuticals
Implied Volatility Surging for Guardian Pharmacy Services Stock Options
by Zacks Equity Research
Investors need to pay close attention to Guardian Pharmacy Services stock based on the movements in the options market lately.
medical medical-devices
4 PEG-Based GARP Picks for Navigating Early-2026 Market Uncertainty
by Urmimala Biswas
PAHC and others highlight how PEG-based GARP picks blend value and growth as markets hit 2026 highs amid rate uncertainty and valuation sensitivity.
basic-materials consumer-discretionary medical medical-devices
Do Options Traders Know Something About FMS Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Fresenius Medical Care stock based on the movements in the options market lately.
medical
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
by Zacks Equity Research
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
biotechnology biotechs medical pharmaceuticals
Select Medical Expands Rehab Footprint Through Vibra Healthcare JV
by Zacks Equity Research
SEM teams up with Vibra Healthcare to run a 76-bed rehab hospital in Southern Kentucky, expanding its post-acute care footprint through a capital-efficient JV.
medical smart-health
BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers
by Zacks Equity Research
Butterfly Network targets a 2026 Beam Steering API, opening core imaging to developers and enabling AI tools in Butterfly Garden.
medical medical-devices
ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves
by Zacks Equity Research
AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.
earnings medical medical-devices
Here's Why You Should Add PacBio Stock to Your Portfolio
by Zacks Equity Research
PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.
medical medical-devices
Is the Options Market Predicting a Spike in BeOne Medicines Stock?
by Zacks Equity Research
Investors need to pay close attention to ONC stock based on the movements in the options market lately.
medical